Clinicopathological and Prognostic Features of Surgical Management in Duodenal Gastrointestinal Stromal Tumors.

about

Clinicopathological and Prognostic Features of Surgical Management in Duodenal Gastrointestinal Stromal Tumors.

Item

http://www.wikidata.org/entity/Q47323711

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Clinicopathological and Progno ...... strointestinal Stromal Tumors.

@en

Clinicopathological and Progno ...... strointestinal Stromal Tumors.

@nl

type

Item

label

Clinicopathological and Progno ...... strointestinal Stromal Tumors.

@en

Clinicopathological and Progno ...... strointestinal Stromal Tumors.

@nl

prefLabel

Clinicopathological and Progno ...... strointestinal Stromal Tumors.

@en

Clinicopathological and Progno ...... strointestinal Stromal Tumors.

@nl

P1476

Clinicopathological and Progno ...... strointestinal Stromal Tumors.

@en

P2093

Birendra Kumar Sah

http://www.w3.org/2001/XMLSchema#string

Chen Li

http://www.w3.org/2001/XMLSchema#string

Hong Peng Shi

http://www.w3.org/2001/XMLSchema#string

Min Lu Huang

http://www.w3.org/2001/XMLSchema#string

Min Yan

http://www.w3.org/2001/XMLSchema#string

Wen Tao Liu

http://www.w3.org/2001/XMLSchema#string

Ya Nan Zheng

http://www.w3.org/2001/XMLSchema#string

Zhen Qiang Wang

http://www.w3.org/2001/XMLSchema#string

Zheng Gang Zhu

http://www.w3.org/2001/XMLSchema#string

Zheng Lun Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

Neoadjuvant imatinib for borderline resectable GIST.

Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.

The effect of surgery and grade on outcome of gastrointestinal stromal tumors.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors.

Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.

Duodenal gastrointestinal stromal tumors: clinicopathological characteristics, surgery, and long-term outcome.

P31

scholarly article

P356

10.1159/000485140

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29232679

http://www.w3.org/2001/XMLSchema#string